上海奥浦迈生物科技股份有限公司 本次交易相关主体买卖股票情况的自查报 告 之 专项核查意见 国泰海通证券股份有限公司 关于 独立财务顾问 二〇二五年六月 上海奥浦迈生物科技股份有限公司（以下简称"上市公司"、"奥浦迈"） 拟发行股份及支付现金购买资产并募集配套资金（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》《公开发行证券的公司信息披露内 容与格式准则第 26 号—上市公司重大资产重组》《监管规则适用指引—上市类 第 1 号》等文件的规定，国泰海通证券股份有限公司（以下简称"独立财务顾问" "国泰海通"）作为本次交易的独立财务顾问，对上市公司本次交易相关内幕信 息知情人买卖股票的自查报告进行了核查，具体情况如下： 一、本次交易的内幕信息知情人买卖股票情况自查期间 根据上市公司披露的公告文件，奥浦迈于 2025 年 1 月 17 日发布《上海奥浦 迈生物科技股份有限公司关于筹划重大资产重组的停牌公告》，首次披露上市公 司正在筹划本次交易，经向上交所申请，上市公司股票于 2025 年 1 月 17 日开市 起停牌。2025 年 6 月 6 日，上市公司披露了《重组报告书（草案）》。 根据《公开发 ...

上海奥浦迈生物科技股份有限公司（以下简称"上市公司"、"奥浦迈"或 "公司"）拟发行股份及支付现金购买澎立生物医药技术（上海）股份有限公司 100%股权并募集配套资金（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》《公开发行证券的公司信息披露内 容与格式准则第 26 号—上市公司重大资产重组》《监管规则适用指引—上市类第 1 号》等文件的要求，公司对本次交易相关内幕信息知情人买卖股票情况进行了 自查，同时根据中国证券登记结算有限责任公司上海分公司出具《信息披露义务 人持股及股份变更查询证明》《股东股份变更明细清单》的查询结果，公司独立 财务顾问国泰海通证券股份有限公司（以下简称"国泰海通"或"独立财务顾 问"）以及上海市方达律师事务所（以下简称"上海方达"或"律师事务所"） 对相关事项进行了核查并出具了专项核查意见，现将相关情况公告如下： 一、本次交易的内幕信息知情人买卖股票情况自查期间 本次交易的内幕信息知情人买卖上市公司股票的自查期间为上市公司为本 次交易申请股票停牌日前 6 个月起至《重组报告书（草案）》披露之前一日止， 即 2024 年 7 月 17 日至 2025 年 6 月 5 日 ...

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 2025 年第一次临时股东大会的法律意见书 致：上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海奥浦迈 生物科技股份有限公司（以下简称"公司"）2025 年第一次临时股东大会（以下 简称"本次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集 会议人员的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-054 上海奥浦迈生物科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一）股东大会召开的时间：2025 年 6 月 23 日 （二）股东大会召开的地点：上海市浦东新区紫萍路 908 弄 28 号楼上海奥浦迈 生物科技股份有限公司五楼公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其 持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 82 | | --- | --- | | 普通股股东人数 | 82 | | 2、出席会议的股东所持有的表决权数量 | 80,742,807 | | 普通股股东所持有表决权数量 | 80,742,807 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 71.1084 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 71.1084 | （四）表决方式是否符合《公 ...

Core Viewpoint - Aopumai's acquisition of Pengli Biotechnology for 1.45 billion is seen as a strategic move to diversify its client base and enhance its early pipeline, despite facing internal dissent and regulatory scrutiny [4][7][9]. Company Overview - Aopumai plans to acquire 100% of Pengli Biotechnology for a total consideration of 1.45 billion, with 710 million needing to be paid in cash, which nearly depletes Aopumai's cash reserves [4][9]. - Aopumai's main business includes cell culture products and services, with a significant reliance on CHO culture media, contributing over 70% of its revenue in 2024 [7][9]. Financial Performance - Aopumai's performance has been declining, with a reported 80% drop in earnings over the past three years, and a net profit of 14.67 million in Q1 2024, down 25.08% year-on-year [9][11]. - The company's cash balance as of Q1 2024 was 737 million, which covers the cash portion of the acquisition, but still represents a significant portion of its total funds [9][11]. Market Context - The acquisition is positioned as a strategic opportunity during a low point in the industry, with Aopumai aiming to integrate early-stage research capabilities through this merger [7][9]. - Pengli Biotechnology, which previously aimed for a listing on the STAR Market, has also faced growth challenges, with a net profit of 44.51 million in 2024, down 25.52% from 2023 [11]. Stock Market Reaction - Following the announcement of the acquisition, Aopumai's stock price showed a slight increase, closing at 38.49 yuan, reflecting market optimism regarding the transaction [12].

Core Viewpoint - The company Aopumai plans to acquire 100% equity of Pengli Bio for 1.451 billion yuan as part of its restructuring efforts, aiming to enhance its service offerings in the CRO sector and improve its asset quality and operational capabilities [2][4]. Group 1: Acquisition Details - Aopumai's acquisition of Pengli Bio is intended to create a comprehensive service chain from early research to commercial production, transitioning from a single product supplier to a comprehensive solution provider [2]. - The independent director of Aopumai, Tao Hua'an, voted against the acquisition, citing a lack of necessity for the merger at this stage [2]. Group 2: Financial Performance - Aopumai's financial performance shows a projected revenue of approximately 297 million yuan for 2024, reflecting a year-on-year increase of 22.26%, while the net profit attributable to shareholders is expected to decline by 61.04% to about 21.05 million yuan [3]. - The company experienced a net profit decline of over 40% in 2023 [3]. Group 3: Financial Impact of the Acquisition - The acquisition is expected to enhance Aopumai's net assets, net profit, and basic earnings per share, while also optimizing its asset-liability structure [4]. - Pengli Bio's gross profit margins for 2023 and 2024 are reported at 47.3% and 42.98%, respectively, indicating a decline due to various factors, although the business remains stable [4]. Group 4: Regulatory and Approval Process - Aopumai has disclosed that there are six groups of parties involved in the transaction with a minor combined shareholding of 2.21%, and no party will hold more than 5% of the company post-transaction [5]. - The company confirmed that all necessary approval procedures for the transaction have been completed, with no outstanding requirements before the shareholders' meeting [5]. Group 5: Background of Pengli Bio - Pengli Bio is a CRO company that provides services for innovative drug development and had previously applied for an IPO on the Sci-Tech Innovation Board, which was ultimately withdrawn [5].

Group 1 - The company plans to acquire 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds from no more than 35 specific investors [1][2] - The company has received an inquiry letter from the Shanghai Stock Exchange regarding the disclosure of the restructuring draft and has actively organized discussions to address the questions raised [1][2] - The company has completed responses to the inquiry letter and has updated the restructuring report to include necessary disclosures and clarifications regarding the transaction and its associated risks [2] Group 2 - The restructuring report has been revised to include details on the decision-making and approval processes that still need to be fulfilled for the transaction [2] - The report also clarifies the specific relationships and agreements between the parties involved in the transaction [2] - Minor adjustments have been made to the restructuring report's content without affecting the overall transaction plan [2]

Core Viewpoint - The company is responding to an inquiry regarding its restructuring plan, emphasizing the necessity and feasibility of the transaction to enhance its business capabilities and asset quality in the biopharmaceutical sector [1][2][3]. Group 1: Transaction Necessity - The transaction is deemed necessary as both the company and the target focus on innovative biopharmaceutical services, with the company specializing in cell culture products and CDMO services, while the target provides CRO services for preclinical research [2][4]. - The merger aims to create synergies in business operations, customer bases, and international strategies, enhancing the overall service offerings from early research to commercial production [5][6]. - The company anticipates that the transaction will allow it to transition from a product supplier to a comprehensive solution provider, thereby improving its market position and customer retention [7][9]. Group 2: Business Integration and Synergy - Post-transaction, the company will expand its service offerings from "cell culture + CDMO" to "cell culture + CRDMO," facilitating a full-service model that integrates various stages of drug development [10][19]. - The integration will enable the company to provide a seamless transition for clients from early drug discovery through to commercial production, enhancing customer satisfaction and loyalty [11][12]. - The company plans to leverage the target's established international business relationships to promote its products in global markets, thereby increasing its market share and brand influence [12][20]. Group 3: Financial Impact and Performance Improvement - The transaction is expected to significantly improve the company's financial metrics, with projected increases in total assets, revenue, and net profit post-merger [13][14]. - The company anticipates a diversification of its customer base, reducing reliance on a single product line and enhancing its resilience against market fluctuations [15][16]. - The merger will also optimize the company's capital structure, improving its debt-to-equity ratio and overall financial health [14][16]. Group 4: Industry Context and Trends - The transaction aligns with industry trends where biopharmaceutical companies are increasingly seeking integrated service providers to streamline their development processes and reduce costs [17][19]. - The merger reflects a broader industry movement towards consolidation, enabling companies to enhance their competitive edge through comprehensive service offerings [18][19]. - The company aims to position itself as a leader in the biopharmaceutical service sector by adopting a more integrated approach to drug development, which is becoming a critical success factor in the industry [17][19].

证券代码：688293 证券简称：奥浦迈 上市地点：上海证券交易所 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套 资金报告书（草案）（修订稿） | 项目 | 交易对方 | | --- | --- | | | PharmaLegacy Hong Kong Limited、嘉兴汇拓企业管理合伙企业 | | | （有限合伙）、红杉恒辰（厦门）股权投资合伙企业（有限合 | | | 伙）、宁波梅山保税港区谷笙澎立投资合伙企业（有限合伙）、 | | | TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙）、杭 | | | 州泰格股权投资合伙企业（有限合伙）、南通东证富象股权投资 | | | 中心（有限合伙）、江西济麟鑫盛企业管理有限公司、中金启辰 | | | 贰期（苏州）新兴产业股权投资基金合伙企业（有限合伙）、嘉 | | | 兴合拓企业管理合伙企业（有限合伙）、苏州晨岭投资合伙企业 | | | （有限合伙）、德州两仪幂方康健创业投资合伙企业（有限合 | | | 伙）、平阳国凯股权投资合伙企业（有限合伙）、苏州一元幂方 | | 发行股份及支付现金购买资产 | 医药创业投资合伙企业（有限合 ...

证券代码：688293 证券简称：奥浦迈 上市地点：上海证券交易所 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套 资金报告书（草案）摘要（修订稿） | 项目 | 交易对方 | | --- | --- | | | PharmaLegacy Hong Kong Limited、嘉兴汇拓企业管理合伙企业 | | | （有限合伙）、红杉恒辰（厦门）股权投资合伙企业（有限合 | | | 伙）、宁波梅山保税港区谷笙澎立投资合伙企业（有限合伙）、 | | | TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙）、杭 | | | 州泰格股权投资合伙企业（有限合伙）、南通东证富象股权投资 | | | 中心（有限合伙）、江西济麟鑫盛企业管理有限公司、中金启辰 | | | 贰期（苏州）新兴产业股权投资基金合伙企业（有限合伙）、嘉 | | | 兴合拓企业管理合伙企业（有限合伙）、苏州晨岭投资合伙企业 | | | （有限合伙）、德州两仪幂方康健创业投资合伙企业（有限合 | | | 伙）、平阳国凯股权投资合伙企业（有限合伙）、苏州一元幂方 | | 发行股份及支付现金购买资产 | 医药创业投资合伙企业（有 ...